LONDON, May 14, 2026, 17:27 (BST)
- Halma finished the day up 2.94% at £46.94, easily beating the FTSE 100, which edged up just 0.46%.
- Next up: full-year results on June 11, which will put the mid-teens organic revenue growth guidance to the test.
- Analyst targets are all over the map, and after the rally, there’s not much room left for mistakes.
Halma plc surged 2.94% Thursday, wrapping up at £46.94 and pulling close to its 52-week high. Traders seemed to position ahead of the company’s full-year numbers due next month. The FTSE 100 added 0.46%. MarketWatch noted Halma’s trading volume landed under its 50-day average.
This shift comes with Halma’s June 11 results looming—investors have already bid up the stock, expecting a strong showing. The company’s financial calendar pegs that day for the 2025/26 full-year numbers, following the March 31 financial year-end.
The June statement isn’t just about the headline figures. Investors want proof that demand, margins, and acquisitions are still aligned, especially after the stock’s steep rally.
Halma stuck with its March outlook, still tracking toward a 23rd consecutive year of record adjusted profit. The company projected organic revenue growth in the mid-teens on a constant-currency basis—excluding most first-year acquisition impacts and currency swings. Adjusted EBIT margin? About 22%. (That’s operating profit before interest, tax, and some acquisition-related items.) Orders outpaced both revenue and last year’s levels. As for cash conversion, Halma said it should hit the 90% target.
Acquisitions still play a role here. Back in March, Halma reported a record £451 million spent across five deals, calculated on a maximum consideration basis. The company moved again in April, picking up California-based Surgistar—known for its ophthalmic instruments—to fold into MicroSurgical Technology as a bolt-on. Chief Executive Marc Ronchetti described cataract and ophthalmic surgery as “long term growth markets,” adding that Surgistar’s products fit “highly complementary” with MST. Halma
Competitive names held up as well, although Halma pulled ahead. Smiths Group put on 2.34% and Spirax Group tacked on 1.49% Thursday—solid gains, both beating the FTSE 100, if not quite matching Halma’s action.
Broker opinions are anything but unified. LSEG numbers compiled by Investors Chronicle list 16 analysts aiming for a 12-month median target on Halma at 4,090p as of May 7—estimates ranged widely, from a bullish 5,060p to a bearish 3,050p. The calls themselves cover the spectrum: two rate it a buy, seven say outperform, eight stick with hold, and one is firmly in the strong sell camp.
Seventeen analysts, polled between Feb. 12 and March 6, are looking for 2025/26 revenue of £2.56 billion and adjusted EBIT of £575.4 million, according to consensus figures published by the company. Halma notes these aren’t its own projections.
There’s a risk the June update arrives as expected, but doesn’t impress. Sterling’s recent strength is likely to drag on reported numbers, and if photonics — that’s the light-based tech behind sensing and analysis — hits a soft patch, defending the organic growth goal just gets tougher. Shares also look vulnerable if rates climb. Right now, Polymarket’s odds put a Bank of England hike in 2026 at 58.5%, and a Reuters poll this week showed most economists still betting on rates sticking at 3.75%, though a growing minority are leaning toward an increase.
Right now, investors are rewarding execution. Halma must prove that its latest rally isn’t running on reputation alone; results have to deliver on orders, cash, and margin.
